Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D.

doi:10.1002/(sici)1097-0215(19980130)75:3<379::aid-ijc9>3.0.co;2-#

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D.

International journal of cancer - 30 Jan 1998

Prados J, Melguizo C, Marchal J A, Vélez C, Alvarez L, Aránega A

Abstract excerpt

Classical cytotoxic treatment of rhabdomyosarcoma (RMS) is accompanied often by significant morbidity and poor response. The use of cytotoxic agents may induce a multidrug resistance phenotype, which plays an important role in the sensitivity of tumoral cells to drugs. Using actinomycin D, a drug...

Topics

ATP Binding Cassette Transporter, Subfamily B, Member 1
Actinin
Antibiotics, Antineoplastic
Cell Differentiation
Dactinomycin
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Flow Cytometry
Humans
Neoplasm Proteins
Phenotype
Polymerase Chain Reaction
Rhabdomyosarcoma
Tropomyosin
Tumor Cells, Cultured
Vimentin

Source

Open in PubMed

Identifiers

PMID: 9455797
DOI: 10.1002/(sici)1097-0215(19980130)75:3<379::aid-ijc9>3.0.co;2-#

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9455797-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics